SCHEMBL15052870

SCHEMBL15052870

[2H]C([2H])(c1ccnc2[nH]ccc12)n1ccc2c(NC(=O)Nc3cc(Br)ccc3OC)cccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 2/20 0.41
KDR P35968 1/20 0.41
TEK Q02763 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.40
MAPT P10636 3/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HPGD P15428 1/20 0.36
CIT O14578 2/20 0.36
BTK Q06187 1/20 0.35
GAA P10253 2/20 0.35
MAPK14 Q16539 1/20 0.35
BRAF P15056 2/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
PKM P14618 1/20 0.34
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15054198 0.95 KDR (0.38) EPHB4KDRTEKIRAK4MAPT
SCHEMBL3702950 0.92 KDR (0.42) EPHB4KDRTEKIRAK4MAPT
SCHEMBL15053596 0.91 PKM (0.43) EPHB4IRAK4MAPTKDM4EMEN1
SCHEMBL15052968 0.91 MEN1 (0.46) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL15052906 0.91 KMT2A (0.40) IRAK4MAPTKDM4EMEN1KMT2A
SCHEMBL15053581 0.91 MEN1 (0.44) EPHB4IRAK4MAPTKDM4EMEN1
SCHEMBL15052831 0.90 MAPT (0.44) MAPTKDM4EMEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL15053468 0.90 MEN1 (0.43) EPHB4IRAK4MAPTKDM4EMEN1
SCHEMBL15054209 0.89 MAPT (0.43) EPHB4KDRTEKIRAK4MAPT
SCHEMBL15053776 0.89 BRAF (0.44) EPHB4KDRTEKMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US claimed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK2, CDK1, CDK3 EPHB4 3126/4885KDR 1965/4885TEK 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.